secwatch / observer
8-K filed May 28, 2026, 9:01 AM ET ticker VIR CIK 0001706431
leadership confidence high sentiment neutral materiality 0.65

Vir Biotechnology director Saira Ramasastry resigns; board shrinks to 7; annual meeting elects directors

Vir Biotechnology, Inc.

Machine-readable event card

schema_version
secwatch.filing_event.v1
accession
0001628280-26-038630
form_type
8-K
ticker
VIR
cik
0001706431
company_name
Vir Biotechnology, Inc.
filed_at
2026-05-28T13:01:18+00:00
discovered_at
2026-05-28T13:02:00.268108+00:00
generated_at
2026-05-28T13:04:22.570135+00:00
sec_items
["5.02", "5.07"]
event_type
leadership
sentiment
neutral
materiality_score
0.65
calibrated_materiality_score
0.65
confidence
high
secwatch_canonical_url
https://secwatch.observer/filing/0001628280-26-038630
json_url
https://secwatch.observer/filing/0001628280-26-038630.json
markdown_url
https://secwatch.observer/filing/0001628280-26-038630.md
text_url
https://secwatch.observer/filing/0001628280-26-038630.txt
edgar_index_url
https://www.sec.gov/Archives/edgar/data/1706431/000162828026038630/0001628280-26-038630-index.htm
edgar_primary_document_url
https://www.sec.gov/Archives/edgar/data/1706431/000162828026038630/vir-20260525.htm
generated_by_model
deepseek-v4-flash:cloud@v2
review_status
machine_generated
human_reviewed
false
corrected
false
correction_note
null
correction_timestamp
null
superseded_by
null

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Saira Ramasastry

Director
VIR · Vir Biotechnology, Inc.
Effective
2026-05-26
Filed
May 28, 2026, 9:01 AM ET
On May 25, 2026, Saira Ramasastry, M.S., M.Phil., a member of the Board of Directors (the Board) of Vir Biotechnology, Inc. (the Company) and Chair of the Company’s Audit Committee (the Audit Committee), informed the Company that, due to a business conflict, she will be stepping down from her role as a member of the Board and the Audit Committee, effective May 26, 2026.

Source-grounded claims

305e0fce20

Saira Ramasastry departed as Director at Vir Biotechnology, Inc..

On May 25, 2026, Saira Ramasastry, M.S., M.Phil., a member of the Board of Directors (the Board) of Vir Biotechnology, Inc. (the Company) and Chair of the Company’s Audit Committee (the Audit Committee), informed the Company that, due to a business conflict, she will be stepping down from her role as a member of the Board and the Audit Committee, effective May 26, 2026.

SEC 8-K Item 5.02 confidence 1.0 SEC evidence

Comparable filings

GPOR

Gulfport Energy appoints Domenic Dell'Osso to Board; CEO role effective May 28, 2026

GULFPORT ENERGY CORP June 1, 2026, 4:10 PM ET leadership Items 5.02, 5.07

same fact type: executive_change same SEC item: 5.02, 5.07 same event type: leadership similar materiality

This filing

On May 25, 2026, Saira Ramasastry, M.S., M.Phil., a member of the Board of Directors (the Board) of Vir Biotechnology, Inc. (the Company) and Chair of the Company’s Audit Committee (the Audit Committee), informed the Company that, due to a business conflict, she will be stepping down from her role as a member of the Board and the Audit Committee, effective May 26, 2026.

Comparable filing

On May 28, 2026, the Board voted to increase the size of the Board to seven members and appointed Domenic J. Dell’Osso, Jr. to serve as a member of the Board until the 2027 Annual Meeting of Stockholders or until his successor is duly elected and qualified.

Filing page SEC filing

MGNO

Magnolia Bancorp names Robert Kimbro President/CEO; Hurley becomes Executive Chair

Magnolia Bancorp, Inc. June 1, 2026, 2:15 PM ET leadership Items 5.02, 5.07, 7.01, 9.01

same fact type: executive_change same SEC item: 5.02, 5.07 same event type: leadership similar materiality

This filing

On May 25, 2026, Saira Ramasastry, M.S., M.Phil., a member of the Board of Directors (the Board) of Vir Biotechnology, Inc. (the Company) and Chair of the Company’s Audit Committee (the Audit Committee), informed the Company that, due to a business conflict, she will be stepping down from her role as a member of the Board and the Audit Committee, effective May 26, 2026.

Comparable filing

On May 28, 2026, both the Company and the Association appointed Robert W. Kimbro as their President and Chief Executive Officer effective as of June 1, 2026.

Filing page SEC filing

BELFA

Bel Fuse names Kenneth Lai as SVP ITDS; annual meeting approves 2026 equity plan

BEL FUSE INC /NJ May 28, 2026, 2:24 PM ET leadership Items 5.02, 5.07, 9.01

same fact type: executive_change same SEC item: 5.02, 5.07 same event type: leadership similar materiality

This filing

On May 25, 2026, Saira Ramasastry, M.S., M.Phil., a member of the Board of Directors (the Board) of Vir Biotechnology, Inc. (the Company) and Chair of the Company’s Audit Committee (the Audit Committee), informed the Company that, due to a business conflict, she will be stepping down from her role as a member of the Board and the Audit Committee, effective May 26, 2026.

Comparable filing

on May 22, 2026, the Company determined to name Kenneth Lai as Senior Vice President ITDS, effective late second quarter or early third quarter of 2026. In this role, Mr. Lai’s responsibilities expand to include the Company’s India and private label operations, in addition to China and other Asia locations. As a result of this change in responsibilities, Mr. Lai is no longer determined to be an “executive officer” or “officer” of the Company as defined in Rules 3b-7 and 16a-1(f) under the Securities Exchange Act of 1934, as amended, respectively.

Filing page SEC filing

HNST

The Honest Company promotes Curtiss Bruce to Chief Financial & Operating Officer and announces annual meeting results

Honest Company, Inc. May 27, 2026, 4:35 PM ET leadership Items 5.02, 5.07

same fact type: executive_change same SEC item: 5.02, 5.07 same event type: leadership similar materiality

This filing

On May 25, 2026, Saira Ramasastry, M.S., M.Phil., a member of the Board of Directors (the Board) of Vir Biotechnology, Inc. (the Company) and Chair of the Company’s Audit Committee (the Audit Committee), informed the Company that, due to a business conflict, she will be stepping down from her role as a member of the Board and the Audit Committee, effective May 26, 2026.

Comparable filing

On May 20, 2026, the Board of Directors of The Honest Company, Inc. (the “Company”) approved the promotion of Curtiss Bruce to the position of Chief Financial & Operating Officer, effective May 21, 2026 (the “Effective Date”).

Filing page SEC filing

CRVL

CorVel CEO Michael Combs to become Executive Chair; Sarah Scott appointed CEO and President effective July 1, 2026

CORVEL CORP June 1, 2026, 5:05 PM ET leadership Items 5.02, 7.01, 9.01

same fact type: executive_change same SEC item: 5.02 same event type: leadership similar materiality

This filing

On May 25, 2026, Saira Ramasastry, M.S., M.Phil., a member of the Board of Directors (the Board) of Vir Biotechnology, Inc. (the Company) and Chair of the Company’s Audit Committee (the Audit Committee), informed the Company that, due to a business conflict, she will be stepping down from her role as a member of the Board and the Audit Committee, effective May 26, 2026.

Comparable filing

In connection with the leadership transition, the Board appointed Sarah Scott to serve as Chief Executive Officer and President of the Company, effective July 1, 2026.

Filing page SEC filing

WTTR

Select Water Solutions COO Skarke moves to Chief Commercial Officer; no successor named

Select Water Solutions, Inc. June 1, 2026, 5:00 PM ET leadership Items 5.02, 9.01

same fact type: executive_change same SEC item: 5.02 same event type: leadership similar materiality

This filing

On May 25, 2026, Saira Ramasastry, M.S., M.Phil., a member of the Board of Directors (the Board) of Vir Biotechnology, Inc. (the Company) and Chair of the Company’s Audit Committee (the Audit Committee), informed the Company that, due to a business conflict, she will be stepping down from her role as a member of the Board and the Audit Committee, effective May 26, 2026.

Comparable filing

Effective June 1, 2026, Michael C. Skarke transitioned from serving as the Executive Vice President and Chief Operating Officer of Select Water Solutions, Inc. (the “Company”) to serving as the Company’s Executive Vice President and Chief Commercial Officer,

Filing page SEC filing

TTD

The Trade Desk appoints Nate Olmstead as CFO effective July 9, 2026; interim CFO Davis resumes CAO role

Trade Desk, Inc. June 1, 2026, 4:35 PM ET leadership Items 5.02, 9.01

same fact type: executive_change same SEC item: 5.02 same event type: leadership similar materiality

This filing

On May 25, 2026, Saira Ramasastry, M.S., M.Phil., a member of the Board of Directors (the Board) of Vir Biotechnology, Inc. (the Company) and Chair of the Company’s Audit Committee (the Audit Committee), informed the Company that, due to a business conflict, she will be stepping down from her role as a member of the Board and the Audit Committee, effective May 26, 2026.

Comparable filing

On June 1, 2026, The Trade Desk, Inc. (the “Company”) announced the appointment of Nate Olmstead, age 54, as the Company’s chief financial officer.

Filing page SEC filing

WST

West Pharmaceutical appoints Michel Lagarde as CEO; Green retires, Friel becomes Chair

WEST PHARMACEUTICAL SERVICES INC June 1, 2026, 4:32 PM ET leadership Items 5.02, 7.01, 9.01

same fact type: executive_change same SEC item: 5.02 same event type: leadership similar materiality

This filing

On May 25, 2026, Saira Ramasastry, M.S., M.Phil., a member of the Board of Directors (the Board) of Vir Biotechnology, Inc. (the Company) and Chair of the Company’s Audit Committee (the Audit Committee), informed the Company that, due to a business conflict, she will be stepping down from her role as a member of the Board and the Audit Committee, effective May 26, 2026.

Comparable filing

As of the Start Date, Mr. Green will resign as a member of the Board and Mr. Lagarde will be appointed as a member of the Board to fill that vacancy.

Filing page SEC filing

Source: SEC EDGAR
accession 0001628280-26-038630

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.